Conatus Pharmaceutic (CNAT) Stock News
NASDAQ:CNAT - Nasdaq -
CNAT Latest News, Press Relases and Analysis
Histogen completes tie-up with Conatus Pharma (NASDAQ:CNAT)
Histogen (HSTO) has finalized its merger with Conatus Pharmaceuticals (NASDAQ:CNAT). The combined company with do business under the Histogen name with shares trading under the HSTO ticker starting to
The Daily Biotech Pulse: Cumberland's Positive Anti-Bacterial Readout, FDA Nods For Bristol-Myers, Astellas
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 26) ADC Therapeutics SA (NYSE:...
30 Stocks Moving in Friday's Pre-Market Session
Gainers Navidea Biopharmaceuticals, Inc. (NASDAQ: NAVB) shares rose 65.2% to $2.18 in pre-market trading after the company reported results of second interim analysis of ongoing...
Best & Worst Performing Small Cap Stocks for May 21, 2020
XTNT – XTNT leads the way today as the best performing small cap stock, closing up 160.28%.
Best & Worst Performing Small Cap Stocks for May 14, 2020
SNNA – SNNA leads the way today as the best performing small cap stock, closing up 34.46%.
Best & Worst Performing Small Cap Stocks for May 8, 2020
PTGX – PTGX leads the way today as the best performing small cap stock, closing up 83.70%.
Best & Worst Performing Small Cap Stocks for May 5, 2020
PTLA – PTLA leads the way today as the best performing small cap stock, closing up 130.03%.
Penny Stocks To Buy Right Now Or Avoid At All Costs?
Do These Make The Cut Of Penny Stocks To Buy Right Now?…
Histogen to Present at BIO CEO & Investor Conference
Histogen and Allergan Expand Cell Conditioned Media (CCM) Skin Care Partnership
Will These Penny Stocks Make Investors Money This Week?
Penny Stocks To Watch After News If there’s one thing that can…
Conatus to merge with Histogen
Conatus Pharmaceuticals (NASDAQ:CNAT) and privately held Histogen have agreed to merge in an all-stock transaction. Conatus shareholders will own ~26% of the combined company while Histogen investors